Terms: = Thyroid cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
1072 results:
1. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
2. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive bioinformatics analysis unveils THEMIS2 as a carcinogenic indicator related to immune infiltration and prognosis of thyroid cancer.
Liu JF; Zou B; Xiang C; Yan HC
Sci Rep; 2024 Apr; 14(1):8156. PubMed ID: 38589421
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
[TBL] [Abstract] [Full Text] [Related]
5. p53-associated miRNAs repress lncRNA ZFAS1 to retard the proliferation of papillary thyroid carcinoma.
Wang G; Wei L; Yang H
Endokrynol Pol; 2024; 75(1):12-19. PubMed ID: 38497385
[TBL] [Abstract] [Full Text] [Related]
6. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
7. Investigating
Teixeira E; Fernandes C; Bungărdean M; Paula ADC; Lima RT; Batista R; Vinagre J; Sobrinho-Simões M; Máximo V; Soares P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338801
[TBL] [Abstract] [Full Text] [Related]
8. Methods for detection of mitochondrial reactive oxygen species in senescent cells.
Salma F; Yassire O; Youssef B; Corinne D; Ameziane El Hassani R
Methods Cell Biol; 2024; 181():33-41. PubMed ID: 38302242
[TBL] [Abstract] [Full Text] [Related]
9. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
10. Establishment and Characterization of Amitrole-Induced Mouse thyroid Adenomatous Nodule-Derived Cell Lines.
Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
[No Abstract] [Full Text] [Related]
11. NGAL Mediates Anaplastic thyroid Carcinoma Cells Survival Through FAS/CD95 Inhibition.
Crescenzi E; Mellone S; Gragnano G; Iaccarino A; Leonardi A; Pacifico F
Endocrinology; 2023 Dec; 165(2):. PubMed ID: 38091978
[TBL] [Abstract] [Full Text] [Related]
12. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract] [Full Text] [Related]
13. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract] [Full Text] [Related]
14. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract] [Full Text] [Related]
15. Presumed Pathogenic Germ Line and Somatic Variants in African American thyroid cancer.
Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
[No Abstract] [Full Text] [Related]
16. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic thyroid cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract] [Full Text] [Related]
17. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
18. Genomic profiling of primary and metastatic thyroid cancers.
Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
[TBL] [Abstract] [Full Text] [Related]
19. Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case-control study.
Liu S; Yan Y; Cui Z; Feng H; Zhong F; Liu Z; Li Y; Ou X; Li W
BMC Cancer; 2023 Nov; 23(1):1149. PubMed ID: 38012622
[TBL] [Abstract] [Full Text] [Related]
20. The p53/ZEB1-PLD3 feedback loop regulates cell proliferation in breast cancer.
Liu BW; Sun N; Lin H; Zhou XJ; Ma HY; Wang X; Cao XC; Yu Y
Cell Death Dis; 2023 Nov; 14(11):751. PubMed ID: 37978168
[TBL] [Abstract] [Full Text] [Related]
[Next]
